 ST. LOUIS SAN DIEGOBUSINESS WIREWugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented preclinical data on WU-NK-101, the companys lead memory natural killer NK cell therapy product, in combination with cetuximab Ctx, at the American Society of ... Wugen Presents Data on WU-NK-101 in Combination with Cetuxim... 